Compounded ophthalmic medications are eye drugs mixed by a pharmacist to create a customized formula, dose or form that isn’t commercially available off the shelf — think tailor-made glasses versus mass-produced frames. Investors track them because they sit at the intersection of steady demand from patients with special needs, variable regulatory oversight, supply-chain and quality risks, and potential pricing or margin differences compared with standard branded or generic eye medicines.
503B outsourcing facilityregulatory
A 503B outsourcing facility is a U.S. FDA-regulated compounder that makes large batches of sterile drugs (like injectable medicines) without needing a prescription for a specific patient, and follows strict manufacturing and quality controls. Investors care because these facilities sit between drugmakers and hospitals—changes in their capacity, safety record, or regulation can quickly affect supply, pricing and liability across the healthcare and pharmaceutical supply chain.
FDA-registeredregulatory
An FDA-registered facility or product is one that has been listed with the U.S. Food and Drug Administration as required for certain medical devices, manufacturers, or establishments — like being entered in an official government directory. It does not mean the FDA has approved or certified safety or effectiveness, but it does mean the operation is subject to inspections and regulatory rules, which affects market access, investor risk assessment, and credibility with customers and partners.
administrative fineregulatory
An administrative fine is a monetary penalty imposed by a government agency for breaking rules or failing to meet regulatory requirements without it being a criminal case. Think of it like a parking ticket for a business: it directly increases costs, can signal compliance problems to customers and regulators, and may affect profits, stock value and the company’s ability to operate or win future contracts—so investors watch them as a measure of regulatory and financial risk.
Board of Pharmacyregulatory
A board of pharmacy is a government regulatory body that licenses and oversees pharmacists, pharmacies, and the distribution of medications within a state or jurisdiction, enforcing safety, record-keeping, and controlled‑substance rules. For investors, its decisions are like a building inspector's stamp—affecting whether a pharmacy can operate, expand, or dispense certain drugs, and influencing compliance costs, legal risk, and revenue stability for companies in healthcare and drug distribution.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
The Montana-based compounder commits to supporting prescribers and patients in wake of competitor’s abrupt exit of California market
MISSOULA, Mont.--(BUSINESS WIRE)--
OSRX, Inc., a leading provider of compounded ophthalmic medications, announced that the company remains fully licensed, fully operational and continues to serve the needs of California ophthalmologists and optometrists, following a significant market shift involving a major competitor.
According to a Feb. 2, 2026 company disclosure, ImprimisRx – the compounding division of Harrow (NASDAQ:HROW) – voluntarily forfeited its California license on February 1 and agreed to pay an administrative fine of approximately $157,000 as part of a settlement agreement reached with the California Board of Pharmacy (CBOP).1 The CBOP previously filed a formal accusation against ImprimisRx in August 2025 outlining multiple causes for discipline.2
This licensing action pertains solely to ImprimisRx and does not affect other 503B outsourcing facilities in good standing with the California Board of Pharmacy, including OSRX.
With many prescribers utilizing compounded ophthalmic medications for post-operative care, glaucoma management, and myopia control, OSRX emphasized its continued operations and the availability of its manufacturing and dispensing services. The FDA-registered and California-licensed 503B outsourcing facility offers a portfolio of compounded ophthalmic formulations and supports both direct‑to‑patient and direct-to-facility dispensing models. OSRX is licensed and operational in all 50 states.
“California clinicians and their patients can rely on OSRX for uninterrupted access to high-quality compounded medications,” said Anthony Sampietro, founder and CEO of OSRX. “We currently support thousands of ophthalmologists and optometrists nationwide and are prepared to assist any practice navigating medication supply changes.”
OSRX is an FDA-registered 503B outsourcing facility dedicated to advancing ophthalmic care through high-quality compounded solutions and dedicated customer support for prescribers and patients. Licensed nationwide, the Montana-based company is trusted by more than 10,000 prescribers and is driven by its mission to deliver A New View of Medicine®. Learn more at www.osrxpharmaceuticals.com.
